Clinical trial
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye…
NCT00215670 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00215670 |
|---|---|
| Title | Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Official title | A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | pegaptanib sodium (Macugen) |
| Enrollment | 125 |
| Start date | Nov 1, 2002 |
| Completion | May 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 3, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: